Konrad Talbot | Alzheimer’s Disease | Best Researcher Award

Posted on by Cognitive Scientist Awards

Assos. Prof. Dr. Konrad Talbot | Alzheimer’s Disease | Best Researcher Award

Dr. Konrad Talbot is a distinguished neuroscientist and Associate Professor at Loma Linda University School of Medicine, serving in the Departments of Neurosurgery, Pathology & Human Anatomy, and Basic Sciences since 2018. He specializes in investigating the pathogenesis and treatment of neurodegenerative and psychiatric disorders, particularly focusing on brain insulin resistance in Alzheimer’s and Parkinson’s diseases. With a Ph.D. in Physiological Psychology from UCLA and extensive postdoctoral training at the University of Pennsylvania, Dr. Talbot has held faculty and research positions at leading institutions such as Cedars-Sinai, UCLA, and UPenn. He is a highly cited researcher (H-index: 34, 9341 citations), with significant NIH and international grant support. He also serves as an editorial board member, reviewer, and invited speaker at global conferences. His work has influenced both fundamental neuroscience and the development of therapeutic strategies for brain diseases.

Profile

🎓 Education

Dr. Konrad Talbot completed his undergraduate (B.A.), master’s (M.A.), and doctoral (Ph.D.) degrees in Psychology with a specialization in Physiological Psychology at the University of California, Los Angeles (UCLA). His academic path reflects a deep commitment to understanding the biological underpinnings of behavior and brain function. He also received formal teaching certification from UCLA’s Instructor Development Program in 1992. His postdoctoral training included pivotal roles at the University of Pennsylvania’s Department of Pathology and Laboratory Medicine and the Center for Neurodegenerative Disease Research (1997–2001), where he developed expertise in brain autopsy and pathology. He furthered his technical capabilities through advanced training in quantitative fluorescence microscopy at Mount Desert Island Biological Laboratory in 2007. His broad educational background forms a strong foundation for his interdisciplinary research and teaching roles across psychology, neurobiology, pathology, and medical sciences.

🧪 Experience

Dr. Talbot’s academic journey spans over three decades, beginning as an Assistant Professor at Mount St. Mary’s College and St. Olaf College, where he taught psychology and mentored numerous students. He transitioned into intensive research roles at the University of Pennsylvania (UPenn) from 1997 to 2012, ascending from postdoctoral investigator to senior research investigator and research faculty. He later held associate research professorships at Cedars-Sinai Medical Center and UCLA. Since 2018, he has served as Associate Professor at Loma Linda University. Dr. Talbot has authored influential studies on brain insulin resistance, taught neuroanatomy to medical residents, supervised postdoctoral and undergraduate research projects, and served in various academic leadership and committee roles. In addition to his research and teaching, he has contributed editorial expertise to high-impact journals and consulted on landmark neuroanatomical atlases. His career reflects a blend of teaching excellence, pioneering research, and interdisciplinary leadership.

🏅 Awards and Honors

Dr. Talbot’s contributions have been widely recognized through prestigious awards and honors. In 2003, he received the T.L.L. Temple Foundation Discovery Award from the Alzheimer’s Association for his groundbreaking work on brain insulin resistance. He was honored as a co-dedicatee of the influential neuroscience text The Mouse Brain in Stereotaxic Coordinates (2008 edition), highlighting his impact on anatomical brain mapping. In 2020, he was inducted into the Sigma Chi Scientific Research Honor Society. His professional affiliations include long-standing memberships with the Society for Neuroscience, Alzheimer Research Forum, Schizophrenia Research Forum, and ISTAART (International Society to Advance Alzheimer Research and Treatment). He has played leadership roles in organizing major scientific conferences, chaired institutional committees, and served on advisory panels. His editorial contributions and invited lectures worldwide further underscore the scientific community’s high regard for his research excellence and thought leadership.

🔬 Research Focus

Dr. Talbot’s research centers on identifying and targeting mechanisms underlying neurodegenerative and psychiatric diseases, with a special emphasis on insulin resistance in the brain. He has pioneered investigations showing that brain insulin resistance plays a critical role in Alzheimer’s and Parkinson’s disease pathogenesis. His NIH-funded work explores the therapeutic potential of incretin receptor agonists—an emerging class of antidiabetics—in reducing brain insulin resistance and improving cognitive function. His collaborative projects with institutions like CUNY, UCLA, and the University of Washington focus on both human brain tissue analysis and preclinical models. Past research includes the molecular biology of schizophrenia, especially dysbindin-related pathways. He holds a U.S. patent application on methods for treating brain insulin resistance, signaling the translational potential of his findings. Dr. Talbot’s research integrates neuropharmacology, pathology, neuroanatomy, and clinical neuroscience, aiming to develop disease-modifying treatments that can halt or reverse progression in cognitive and psychiatric disorders.

✅ Conclusion

Dr. Konrad Talbot is an accomplished neuroscientist whose multidisciplinary work in brain insulin resistance has significantly advanced understanding and treatment approaches for Alzheimer’s and Parkinson’s diseases, blending rigorous research, impactful teaching, and translational innovation.

Publications

Vahid Rashedi | Alzheimer’s disease | Best Researcher Award

Posted on by Cognitive Scientist Awards

Dr. Vahid Rashedi | Alzheimer’s disease | Best Researcher Award

Dr. Vahid Rashedi 👨‍⚕️, an esteemed Assistant Professor of Gerontology at the University of Social Welfare and Rehabilitation Sciences 🇮🇷, has made outstanding global contributions in aging, cognition, and psychogeriatrics 🌍🧠. With a Ph.D. in Gerontology (2017) 🎓 and extensive editorial duties across high-impact journals 📚, he’s actively involved as a Senior Collaborator with the Global Burden of Disease Project at IHME, University of Washington 🇺🇸. Recognized as a Top 1% scientist by Stanford University in 2024 🏅, he combines academic excellence, innovation, and impactful research. His interdisciplinary work spans gerontology, rehabilitation, mental health, and cognitive science, cementing his status as a global leader in aging research 🌐💡.

Profile

Education 🎓

Dr. Rashedi began his academic path with a Bachelor’s and Master’s degree in Rehabilitation Sciences 🎓🦾, focusing on geriatric care and assistive technology. He earned his Ph.D. in Gerontology with distinction in 2017 🥇, building expertise in psychogeriatrics, mental health, and cognitive decline. His academic training was rooted in interdisciplinary frameworks linking medicine, psychology, and social work 🔬💬. This diverse education empowered him to bridge clinical insights with research, enabling innovative health solutions for elderly populations 👵👴. He complements formal education with global scientific memberships and ongoing collaborations with prestigious institutes, such as IHME 🌎, emphasizing lifelong learning and cutting-edge research.

Experience 👨‍🏫

Dr. Rashedi has over a decade of rich academic and research experience, currently serving as Assistant Professor at the University of Social Welfare and Rehabilitation Sciences 🏫. Since 2019, he has been a Senior Collaborator at IHME, University of Washington, contributing to the Global Burden of Disease project 📊🌐. He has authored 126 indexed journal articles 📑, published a book 📖, and holds four patents, including rehabilitation innovations like the vibrating ankle-foot orthosis 🦿. He is a prolific editorial board member and associate editor for over 10 international journals 📘🖋️. His work in psychogeriatrics and cognition has garnered global recognition, highlighting his leadership and mentoring roles 👨‍🏫🏅.

Awards & Recognitions 🏅

Dr. Rashedi is recognized globally for his scientific excellence, notably ranked in the Top 1% of scientists worldwide by Stanford University in 2024 🌟📈. He holds editorial roles in Frontiers, CGJ, and the Journal of Gerontology, reflecting scholarly esteem 📚. He is a trusted reviewer for numerous high-impact journals and was honored with national and international awards 🥇. His patented inventions in geriatric rehabilitation demonstrate a blend of innovation and clinical value 💡🏥. His GSA, APA, and ISTAART memberships validate his international standing 👏🌐. These honors underscore his unwavering dedication to improving elderly lives through evidence-based science and collaboration 🤝

Research Interests 🔬

Dr. Rashedi’s research delves into psychogeriatrics, mental health, and cognitive disorders in aging populations 🧠👴. As part of the Global Burden of Disease team at IHME 🌍, he contributes to global health analytics, shaping international aging policies 📊. His innovations include assistive devices with therapeutic functions, bridging technology and clinical rehabilitation 🛠️⚙️. With 63 research projects and over 26,000 citations 🔍📈, his scholarly output is extensive and impactful. He leads investigations on dementia, geriatric depression, and cognitive resilience, supported by his roles in editorial boards and scientific societies 🧬📘. His mission is to translate research into real-world health solutions for aging communities 🌟🩺.

Publications 

LUCIANO VITORINO | Cognitive Aging | Cognitive Aging Excellence

Posted on by Cognitive Scientist Awards

Dr. LUCIANO VITORINO | Cognitive Aging | Cognitive Aging Excellence

Dr. Luciano Magalhães Vitorino, Ph.D., RN 🇧🇷 is a dedicated professor at the Faculty of Medicine of Itajubá, Brazil 🏥, with expertise in nursing, gerontology, spirituality, and health 🌱. He has built a multidisciplinary academic and research career blending healthcare, cognition, and spirituality 🧠🙏. With over 1,500 citations 📚 and extensive teaching roles in medicine and nursing 🩺, he leads the Research Center and the Assessment Center at FMIT, actively contributing to the Research Ethics Committee 👨‍🔬. His international academic collaborations, including the University of Alberta 🇨🇦, reflect his global engagement 🌍. A recognized academic voice, he served as Guest Editor for Frontiers in Psychiatry 📰 and holds memberships across academic platforms 📊. Through education, mentorship, and pioneering research, Dr. Luciano is influencing healthcare for the aging population 💡👴👵.

Profile

Education 🎓

Dr. Luciano holds a Postdoctoral Fellowship in Cognition, Spirituality, and Aging from UFJF (2017–2019) 🧘‍♂️🧠, a Ph.D. and M.Sc. in Quality of Life & Spiritual Health from UNIFESP (2012–2016) 📖, and a B.Sc. in Nursing from Faculty of Nursing Wenceslau Braz (2006) 🩺. He specialized in Urgency and Emergency Care (2008–2010) ⛑️. His Ph.D. work was guided by experts from UNIFESP and the University of Alberta 🇨🇦, exploring spiritual/religious coping among older adults. His dissertation and thesis focused on quality of life and religious coping in nursing homes and community settings 🙏🏘️. His postdoctoral project assessed spirituality’s influence on cognitive decline in aging populations 🧓. This unique education, combining nursing, public health, and spirituality, positions him as a thought leader in holistic geriatric care

Experience 👨‍🏫

Dr. Luciano is a full-time assistant professor at FMIT since 2018 👨‍🏫. He coordinates both the Research Center (since 2022) and Assessment Center (since 2022), and is a long-standing member of the Research Ethics Committee (since 2019) 🧪📋. He previously taught at Faculty of Nursing Wenceslau Braz (2007–2012), Medical School of Itajubá (2013–2014), and Federal University of São Paulo (2013) 👨‍⚕️📘. He’s also guided health residency programs and coordinated caregiver training for elderly individuals 👵👨‍⚕️. As Guest Editor of Frontiers in Psychiatry (2022–2023), he shaped international discussions on spirituality and health 🗞️🕊️. His teaching subjects include Epidemiology, Geriatrics, Medical Semiology, and Spirituality & Health 🧬🩻. His roles reflect a passion for interdisciplinary health sciences and dedication to ethical, evidence-based care 🌟.

Awards & Recognitions 🏅

Dr. Luciano’s impactful research and teaching have earned him numerous citations across Scopus (h-index 13, 525 citations), Web of Science (h-index 11, 454 citations), Google Scholar (h-index 20, 1,506 citations) 📈, and ResearchGate (h-index 16, 864 citations) 🧑‍🔬. His inclusion as Guest Editor for Frontiers in Psychiatry (2022–2023) showcases recognition in global academic communities 🌍. He’s contributed to leading Brazilian and international institutions like UNIFESP, UFJF, and the University of Alberta 🇧🇷🇨🇦. Through strong publication records and global collaborations, he’s established himself as an authority on spiritual health in aging 🚀📚. His profile on Google Scholar, ORCID, and LinkedIn reflects international engagement and scholarly distinction 🌐🎖️.

Research Interests 🔬

Dr. Luciano’s research bridges Geriatrics, Gerontology, Spirituality and Mental Health, and AI in Healthcare 🧓🧠💻. His central interest lies in understanding how spirituality and religiosity affect cognitive aging and quality of life 🌿🧘‍♂️. His postdoctoral research—a 4-year longitudinal study—explored how spiritual coping impacts cognitive decline in community-dwelling elders 🧪🕯️. He also investigates medical education, primary healthcare, and interdisciplinary training 🩺📘. As AI transforms healthcare, he examines its integration with geriatric care and spiritual health frameworks 🤖❤️. Through mixed-methods research and international collaboration, he aims to personalize elderly care and mental wellness using both humanistic and data-driven approaches 📊✨.

Publications 

Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Posted on by Cognitive Scientist Awards

Ms. Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Assistant Professor, Alliance University, United Kingdom

🧠 Dr. Jeevitha Gowda R is a dedicated research scholar specializing in cognitive neuroscience and public health, with a strong focus on dementia prevention. She has expertise in developing cognitive screening tools, conducting neuropsychological assessments, and designing neuroscience-based interventions to enhance brain health. Currently serving as a Guest Faculty and Research Associate, she is passionate about bridging research with real-world applications. With proficiency in EEG, ERP, and data analysis, her work emphasizes cognitive aging, behavioral psychology, and mental well-being. Her research contributions include multiple conference presentations, publications, and cognitive training programs. She has received prestigious recognitions, including Best Paper Awards and research fellowships. Her commitment extends to community mental health programs, where she collaborates with NGOs and research institutions. Through her work, she aims to advance cognitive neuroscience and improve public health outcomes. 📚🔬

Profile

Education 🎓

🎓 Dr. Jeevitha Gowda R holds a Ph.D. in Cognitive Neuroscience and Public Health from Ramaiah University of Applied Sciences, Bengaluru (Thesis Submitted), focusing on developing cognitive tools for early dementia detection in primary healthcare settings. She earned a Master’s in Cognitive Neuroscience from JSS Academy of Higher Education, Mysuru (2018), ranking among the top 3 students, with coursework in neural cognition, psychological assessment, and clinical interventions. Her dissertation explored mental fatigue due to sleep deprivation using EEG and ERP. She completed her Bachelor’s in Life Sciences from JSS College for Women, Mysuru (2016), excelling in biochemistry, microbiology, and environmental psychology. Additionally, she trained at the Defence Institute of Psychological Studies (DRDO) and Narayana Health, Bengaluru, gaining hands-on experience in EEG, neuropsychological assessments, and cognitive therapy. Her interdisciplinary education combines neuroscience, psychology, and public health, preparing her for impactful research and innovation in brain health. 🧠📖

Experience 👨‍🏫

💼 Dr. Jeevitha Gowda R has extensive experience as a Research Associate at the Centre for Integrative Health and Well-Being (2020–Present), where she develops neuropsychological intervention tools and conducts cognitive behavioral therapy (CBT) programs. She also serves as a Senior Research Associate at Brighter Minds, focusing on cognitive enhancement and neuroscience-based training programs. As a Guest Lecturer at Ramaiah University of Applied Sciences (2021–Present), she teaches biostatistics, neurophysiology, and psychology. Her past clinical internships at DRDO and Narayana Health provided her with hands-on expertise in EEG, ERP, and neuropsychological assessments. She has conducted research on cognitive impairment, dementia screening, and sleep deprivation’s effects on cognition. Additionally, she has authored 50+ neuroscience articles, presented at international conferences, and collaborated with NGOs for mental health awareness. Her diverse experience integrates academic, clinical, and research-based expertise to advance cognitive neuroscience and public health. 🏥📊

Research Interests 🔬

🔬 Dr. Jeevitha Gowda R’s research bridges cognitive neuroscience, psychology, and public health, focusing on early dementia detection, cognitive aging, and neuropsychological interventions. She specializes in developing culturally relevant cognitive screening tools for primary healthcare, improving accessibility to dementia diagnostics. Her work explores neuropsychological assessments, EEG-based cognitive analysis, and behavioral interventions for enhancing mental well-being. She has conducted studies on sleep deprivation, cognitive impairment, and neurofeedback therapy. She collaborates with institutions like DRDO, Narayana Health, and Brighter Minds to implement neuroscience-driven programs. Her research extends to the psychological well-being of dementia caregivers, neurocognitive training for brain health, and integrating technology into mental health solutions. Through interdisciplinary studies and global research collaborations, she aims to advance early dementia detection methods and improve cognitive health strategies. Her work contributes to policy-making, clinical psychology, and public health initiatives. 🏥📊

Awards & Recognitions 🏅

🏆 Dr. Jeevitha Gowda R has received multiple accolades for her contributions to cognitive neuroscience and public health research. She won the Best Paper Award at the Epidemiology Foundation of India Conference (2023, Goa) for her groundbreaking work on dementia screening. Her research paper on cognitive tool validation earned a Special Mention at the International Dementia Conference (DEMCON-2024, IISC Bangalore). During her master’s, she ranked among the top 3 dissertations at JSS Academy of Higher Education. She was awarded the Senior Research Fellowship (SRF) by Ramaiah University of Applied Sciences (2022–2024) for her Ph.D. research. She has also secured research grants for projects on dementia detection and cognitive enhancement. Recognized for her impactful contributions, she collaborates with prestigious institutions, including DRDO and Narayana Health, to advance neuropsychological research. Her work continues to shape innovations in mental health and aging. 🎖️🧠

Publications 📚

  • Jeevitha Gowda R, Anish Mehta, Krishnamurthy Jayanna. (2025).
    Dementia: A Public Health Challenge in India. South Eastern European
    Journal of Public Health, 29–43. Retrieved from
    hps://www.seejph.com/index.php/seejph/article/view/3295 (Scopus)

  • Jeevitha Gowda R. The Impact of Cultural Beliefs and Stigma on
    Dementia Care and Diagnosis: A Scoping Review, 25 November 2024,
    PREPRINT (Version 1) available at Research Square
    hps://doi.org/10.21203/rs.3.rs-5519592/v1
  • Jeevitha Ramesh, Parimala Guruprasad (2024) Factors Affecting the
    Psychological Well-Being of Caregivers of Dementia Patients: A
    Thematic Review. Journal of Neurology Research Reviews & Reports.
    SRC/JNRRR-260
  • Development and Validation of Cognitive Screening Tools for
    Dementia Detection in Primary Care Seings: An Exploratory Pilot
    Study – Under review at International Journal of Geriatric Psychiatry.
    (Corresponding Author)
  • Burden of Cognitive Impairment Including Dementia, and Associated
    Risk Factors Among the Rural Population of South Karnataka, India –
    Under review at Journal of Public Health Research. (Corresponding
    Author)
  • Impact of Training Module on Lifestyle and Healthy Behaviours: An
    Exploratory Pilot in India – Under review at Journal Explore.
    (Co-Author)

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Posted on by Cognitive Scientist Awards

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication

Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

Posted on by Cognitive Scientist Awards

Dr. Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

 

 

Profile

Education

He completed his education at Org. Kenan Evren School from 2000 to 2008, followed by Gaziantep Anadolu High School from 2008 to 2012. He then pursued his medical training at Hacettepe University Faculty of Medicine from 2012 to 2018. After earning his medical degree, he continued his specialization in Plastic, Reconstructive, and Aesthetic Surgery as a resident at Hacettepe University Faculty of Medicine from November 2018 to February 2024. In April 2024, he joined Ankara Research and Training Hospital, where he continues to work in the Department of Plastic, Reconstructive, and Aesthetic Surgery.

 

Work experience

He has participated in various courses and workshops to enhance his expertise in plastic, reconstructive, and aesthetic surgery. He attended the Resident Ethics Course at Hacettepe University’s Department of History of Medicine and Medical Ethics on January 10-11, 2019. He also completed the 5th Basic Residency School organized by the Turkish Society of Plastic, Reconstructive, and Aesthetic Surgery in Bolu, Turkey, from January 22-25, 2020. Further advancing his skills, he took part in the 15th Advanced Residency School in Antalya, Turkey, from April 20-24, 2023. Additionally, he attended the 1st Cadaver Course of Craniofacial Anomaly and Maxillofacial Surgery at Hacettepe University on September 3-4, 2022, and the 1st Cadaver Course of Orthognathic Surgery at Koc University Hospital in Istanbul, Turkey, on September 7-8, 2022.

In addition to his clinical and surgical training, he has contributed to academic literature by co-authoring book chapters. He co-wrote Age-Related Changes in Trunk Aesthetics in Beauty, Aging, and Anti-Aging (1st ed., Elsevier, 2022) alongside G. G. Üstün and S. Yıldızdal. He also contributed to Dudak ve Damak Yarıkları Hacettepe Ekip Yaklaşım, co-authoring “Apert and Crouzon Syndrome” with İbrahim Vargel.

Awards

He has achieved remarkable academic success, securing 16th place in the National Examination for Specialty in Medicine among over 18,000 participants. Additionally, he ranked 571st in the National Student Selection and Placement Examination out of more than 2 million candidates.

He has actively participated in national meetings within his field, contributing to discussions and advancements in plastic, reconstructive, and aesthetic surgery. He attended the 41st National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Samsun, Turkey, from October 26-30, 2019. He also participated in the National Turkish Plastic Reconstructive and Aesthetic Surgery Eastern Mediterranean Meeting on Cleft Lip and Palate, held in Gaziantep, Turkey, from February 7-9, 2020. Furthermore, he attended the 43rd National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Antalya, Turkey, from November 10-14, 2021.

 

Publication

Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Posted on by Cognitive Scientist Awards

Prof Dr. Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Michal Schwartz (born 1 January 1950) is a professor of neuroimmunology at the Weizmann Institute of Science. She is active in the field of neurodegenerative diseases, particularly utilizing the immune system to help the brain fight terminal neurodegenerative brain diseases, such as Alzheimer’s disease and dementia.[3][1]

Schwartz’s studies have shown that the immune system supports a healthy brain’s function and is vital for healing and protecting the brain in case of injury or disease.[4]

Schwartz coined the term protective autoimmunity[5] and discovered roles for immune cells in repair and neurogenesis. She has been the elected chair of the International Society of Neuroimmunology (ISNI) since 2016.[6]

In 2023 Schwartz received the honorary Israel Prize for Life Sciences.

 

Profile

Education

Schwartz gained her Bachelor of Science in chemistry at the Hebrew University of Jerusalem in 1972. She received her Ph.D in Immunology in 1977 at the Weizmann Institute of Science, where she would later spend the majority of her career. She also spent time at the University of Michigan, Ann Arbor, researching nerve regeneration.[when?

 

Work experience

At the Weizmann Institute, she progressed from senior scientist in the Department of Neurobiology to full professor in 1998, and was then awarded the Maurice and Ilse Katz Professorial Chair in Neuroimmunology in 2016.[7] Schwartz’s work in neuroimmunology has encompassed a wide range of pathologies in the central nervous system (CNS), including injury, neurodegeneration, mental dysfunction, and aging. She coined the term protective autoimmunity and demonstrated the role of immune cells such as macrophages and T cells in spinal cord repair. She also identified specific brain areas for ‘cross talk’ between the CNS and the immune system. This cross-talk is important for recruiting immune cells and maintaining a healthy brain, and the disruption of this cross-talk can play a role in brain aging and neurodegenerative disease. She also showed this role in pregnancy and fetal brain development, where immune disruption in the mother can be linked to neurodevelopmental disorders in their children. Another focus of her work has been on repurposing cancer immunotherapies such as PD-1 blockers to treat neurodegenerative disorders, such as Alzheimer’s disease.

Macrophages

The Schwartz team discovered that bone marrow-derived macrophages are needed for central nervous system (CNS) repair. The brain-resident myeloid cells (the microglia), and infiltrating monocyte-derived macrophages are not redundant populations, despite their myeloid phenotype, and display distinct functions in resolution of brain inflammation.[8][9][10]

Autoimmunity

In her research, Schwartz discovered that the ability to cope with sterile CNS injuries requires support in the form of an adaptive immune response mediated by CD4+ T cells that recognize CNS antigens. She coined the concept of protective autoimmunity, to distinguish this response from autoimmune disease, in which the anti-self response escapes control. Over the years, it became clear that adaptive immunity is needed to facilitate the recruitment of immunoregulatory cells, including bone marrow-derived macrophages and FoxP3 regulatory T cells, though the balance between regulatory T cells and effector memory cells is different in the periphery versus the brain.[11][12][13]

Brain Homeostasis

Schwartz’s team discovered the role of adaptive systemic immune cells, and specifically T cells recognizing brain antigens (Protective autoimmune T cells), in supporting the cognitive capacity of the healthy brain, for lifelong neurogenesis, and functional brain plasticity. These observations paved the way for numerous additional discoveries in which the brain-immune axis was described.[14][15][16]

The Choroid Plexus

Schwartz’s team identified the brain’s choroid plexus (CP) within the blood-cerebrospinal fluid barrier as an immunological interface between the brain and the immune system. It serves as a niche that hosts immune cells, and as a physiological entry gate for leukocytes. Focusing on this unique niche within the brain led the Schwartz group to propose that IFN-γ holds the key to regulating CP gateway activity. Her team further showed that in brain aging and neurodegenerative diseases (studied using both mouse models and human samples), dysfunction of this interface is determined both by signals originating in the brain, and signals from the aged immune system, which led to the identification of Type-I Interferon (IFN-I) at the CP as a negative player, affecting the fate of the aging brain in general, and of microglia, in particular. A similar IFN-I signature at the CP was subsequently discovered by others in Alzheimer’s disease and in the postmortem brains of infected patients who died from COVID-19.[17][14][10]

Immunotherapy

The discovery that adaptive immunity plays a key role in brain function and repair, the need for bone marrow-derived macrophages to resolve local brain inflammation, the fact that Alzheimer’s disease (AD) and all forms of dementia are mainly age-related diseases, and the fact that the immune system is particularly affected by aging all led Schwartz to propose a new treatment for combating dementias. Schwartz suggested empowering systemic immunity, using a form of immunotherapy by modestly blocking the inhibitory immune checkpoint PD1/PD-L1 pathway.[citation needed] This treatment drives an immune-dependent cascade of events, that allows the harnessing of bone marrow-derived macrophages and regulatory T cells to help clear toxic factors from the diseased brain, and to arrest the local inflammation, thereby providing a comprehensive multi-factorial therapy through modification of multiple elements that go awry in AD. Schwartz’s patents for developing such immunotherapy for AD are licensed to a small Biopharma company, Immunobrain Checkpoint. The company is awaiting a clinical trial in AD patients, supported in part by the National Institute of Aging, the US National Institutes of Health, and The Alzheimer’s Association.[18][19][20][21][22][23]

Publication

1. Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame T, Peralta Ramos
J, Cahalon L, Krizhanovsky V, Schwartz M. 2024. Senescent microglia conserved in aging and
Alzheimer’s disease exhibit elevated TREM2 protein levels. Nat Neurosci 27: 1116-24
2. Tsitsou-Kampeli A, Suzzi S, Kenigsbuch M, Satomi A, Strobelt R, Singer O, Feldmesser E, Purnapatre
M, Colaiuta SP, David E, Cahalon L, Hahn O, Wyss-Coray T, Shaul Y, Amit I, Schwartz M. 2023.
Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis. Cell Rep
Med: 101278
3. Suzzi, S. Croese T., Ravid A., Gold O., Clark A., Medina A., Kitsberg D., Adam M., Vernon K., Kohnert
E., Shapira I., Malitsky S., Itkin M., Brandis A., Mehlman T., Salame T., Colaiuta S., Cahalon L.,Slyper
M., Greka A., Habib N., Schwartz M. 2023. N-acetylneuraminic acid links immune exhaustion and
accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model 2023. Nat. Commun.
14:1293.
4. Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, Hajbi R, Schwikowski B, Bodenmiller B, Fu
H, Schwartz M*, Amit I* (equal contribution, and corresponding authors). 2022. A shared diseaseassociated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25: 876-86.
5. Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, Croese T, Burgaletto
C, Baruch K, Ulland T, Colonna M, Weiner A, Amit I, Schwartz M. 2022. Alzheimer’s disease
modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in
mouse model of amyloidosis. Nature Aging 2: 60-73 (citations:17).
6. Ben-Yehuda H, Arad M, Peralta Ramos JM, Sharon E, Castellani G, Ferrera S, Cahalon L, Colaiuta SP,
Salame TM, Schwartz M. 2021. Key role of the CCR2-CCL2 axis in disease modification in a mouse
model of tauopathy. Mol Neurodegeneration 16: 39. (citations:20).
7. Cohen M, Giladi A, Raposo C, Zada M, Li B, Ruckh J, Deczkowska A, Mohar B, Shechter R, Lichtenstein
RG, Amit I, Schwartz M. 2021. Meningeal lymphoid structures are activated under acute and chronic
spinal cord pathologies. Life Sci Alliance 4: e202000907.
8. Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D,
Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M. 2020. Disease- associated
astrocytes in Alzheimer’s disease and aging. Nat Neurosci 23: 701-6. (citations:617).
9. Ben-Yehuda H, Matcovitch-Natan O, Kertser A, Spinrad A, Prinz M, Amit I, Schwartz M. 2020.
Maternal Type-I interferon signaling adversely affects the microglia and the behavior of the offspring
accompanied by increased sensitivity to stress. Mol Psychiatry 25: 1050-67 (Cover page).
10. Kertser A,Baruch K, Deczkowska A,Weiner A,Croese T, Kenigsbuch M,CooperI, Tsoory M,Ben- Hamo
S, Amit I, Schwartz M. 2019. Corticosteroid signaling at the brain-immune interface impedes coping with
severe psychological stress. Sci Adv 5: eaav4111. (citations:32).
11. Rosenzweig N, Dvir-Sternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P,
Cahalon L, Kertser A, Baruch K, Amit I, Weiner A, Schwartz M. 2019. PD-1/PD-L1 checkpoint blockade
harnesses monocyte-derived macrophages to combat cognitive impairment in a mouse model of tauassociated dementia. Nat Commun. 10: 465. (citations:141).
12. Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A,
Singer O, David E, Winter RD, Smith KL, Kertser A, Baruch K, Rosenzweig N, Terem A, Prinz M,
Villeda S, Citri A, Amit I, Schwartz M. 2017. Mef2C restrains the microglial inflammatory response and
is lost in brain ageing in an IFN-I-dependent manner. Nat Commun 8: 717. (citations:212).
13. Cohen M, Ben-Yehuda H, Porat Z, Raposo C, Gordon S, Schwartz M. 2017. Newly formed endothelial
2
cells regulate myeloid cell activity following spinal cord injury via expression of CD200 ligand. J
Neurosci 37: 972-85.